$EVFM $EVFM "Now what While Pelletier deciding to offload shares of the company is noteworthy, it isn't the endgame; it's important to focus on the fundamentals of the business as well. How does Evofem Biosciences fare in that regard? Note that the company currently has just one product on the market, which is an on-demand birth-control gel called Phexxi. This product was approved by the U.S. Food and Drug Administration in late May, and it has become commercially available as of this month. Evofem Biosciences estimates Phexxi's market opportunity to be north of $1 billion.